Ahead of expected objections by European regulators Wednesday to its deal to acquire Grail, Illumina defended itself in papers submitted to the agencies Tuesday.
Illumina is anticipating a formal bloc objection to the $8 billion Grail buyout, it said in a briefing document for EU competition authorities, and tried to preempt the move by asserting the deal is not anti-competitive. It’s an argument Illumina has used previously, but it’s unclear whether or not the new brief will prove persuasive.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,